Plasma Cell Labeling Index

  • Philip R. Greipp
  • Shaji Kumar
Part of the Methods in Molecular Medicine™ book series (MIMM, volume 113)


Multiple myeloma is characterized by proliferation of monoclonal plasma cells (PCs), mostly in the bone marrow. The proliferative rate of the malignant plasma cell is an important determinant of the disease biology and can be measured as the percentage of PCs in the S-phase of the cell cycle. This percentage, or PC labeling index, can be measured using a slide-based immuno- fluorescence method using an antibody against 5-bromo-2′-deoxyuridine, which is actively incorporated by DNA of the dividing PCs. This technique, which can be performed using bone marrow or peripheral blood specimens, also utilizes concurrent cytoplasmic staining against immunoglobulin as well as κ and λ light chains. Employment of cytoplasmic immunoglobulin staining allows more specific identification of PCs as well as confirmation of the monoclonal nature of the PC population. The staining procedure, which can be done manually or using an automated stainer, as well as the process of reading and interpreting these slides is described in detail. The bone marrow peripheral blood labeling index is an important clinical test, providing valuable diagnostic and prognostic information.

Key Words

Multiple myeloma plasma cell cell proliferation bromodeoxyuridine cell cycle immuno-fluorescence microscopy cell kinetics labeling index 


  1. 1.
    Witzig T. E., Gonchoroff N. J., Katzmann J. A., Therneau T. M., Kyle R. A., and Greipp P. R. (1988) Peripheral blood B cell labeling indices are a measure of disease activity in patients with monoclonal gammopathies. J. Clin. Oncol. 6, 1041–1046.PubMedGoogle Scholar
  2. 2.
    Greipp P. R., Witzig T. E., and Gonchoroff N. J. (1985) Immunofluorescent plasma cell labeling indices (LI) using a monoclonal antibody (BU-1). Am. J. Hematol. 20, 289–292.PubMedCrossRefGoogle Scholar
  3. 3.
    Greipp P. R. and Kyle R. A. (1983) Clinical, morphological, and cell kinetic differences among multiple myeloma, monoclonal gammopathy of undetermined significance, and smoldering multiple myeloma. Blood 62, 166–171.PubMedGoogle Scholar
  4. 4.
    Gonchoroff N. J., Katzmann J. A., Currie R. M., et al. (1986) S-phase detection with an antibody to bromodeoxyuridine: role of DNase pretreatment. J. Immunol. Methods 93, 97–101.PubMedCrossRefGoogle Scholar
  5. 5.
    Witzig T. E., Dhodapkar M. V., Kyle R. A., and Greipp P. R. (1993) Quantitation of circulating peripheral blood plasma cells and their relationship to disease activity in patients with multiple myeloma. Cancer 72, 108–113.PubMedCrossRefGoogle Scholar
  6. 6.
    Greipp P. R., Witzig T. E., Gonchoroff N. J., et al. (1987) Immunofluorescence labeling indices in myeloma and related monoclonal gammopathies. Mayo Clin. Proc. 62, 969–977.PubMedGoogle Scholar
  7. 7.
    Witzig T. E., Gonchoroff N. J., Ahmann G. A., Katzmann J. A., and Greipp P. R. (1991) T cell depletion using anti-CD2 coated magnetic beads simplifies the detection of peripheral blood plasma cells. J. Immunol. Methods 144, 253–256.PubMedCrossRefGoogle Scholar
  8. 8.
    Durie B. G., Salmon S. E., and Moon T. E. (1980) Pretreatment tumor mass, cell kinetics, and prognosis in multiple myeloma. Blood 55, 364–372.PubMedGoogle Scholar
  9. 9.
    Greipp P. R., Katzmann J. A., O’Fallon W. M., and Kyle R. A. (1988) Value of beta 2-microglobulin level and plasma cell labeling indices as prognostic factors in patients with newly diagnosed myeloma. Blood 72, 219–223.PubMedGoogle Scholar
  10. 10.
    Greipp P. R., Lust J. A., O’Fallon W. M., Katzmann J. A., Witzig T. E., and Kyle R. A. (1993) Plasma cell labeling index and beta 2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma. Blood 81, 3382–3387.PubMedGoogle Scholar
  11. 11.
    Pettersson D., Mellstedt H., and Holm G. (1980) Monoclonal B lymphocytes in multiple myeloma. Scand. J. Immunol. 12, 375–382.PubMedCrossRefGoogle Scholar
  12. 12.
    Witzig T. E., Kimlinger T. K., Ahmann G. J., Katzmann J. A., and Greipp P. R. (1996) Detection of myeloma cells in the peripheral blood by flow cytometry. Cytometry 26, 113–120.PubMedCrossRefGoogle Scholar
  13. 13.
    Billadeau D., Greipp P., Ahmann G., Witzig T., and Van Ness B. (1995) Detection of B-cells clonally related to the tumor population in multiple myeloma and MGUS. Curr. Top. Microbiol. Immunol. 194, 9–16.PubMedGoogle Scholar
  14. 14.
    Berenson J., Wong R., Kim K., Brown N., and Lichtenstein A. (1987) Evidence for peripheral blood B lymphocyte but not T lymphocyte involvement in multiple myeloma. Blood 70, 1550–1553.PubMedGoogle Scholar

Copyright information

© Humana Press Inc. 2005

Authors and Affiliations

  • Philip R. Greipp
    • 1
  • Shaji Kumar
    • 2
  1. 1.HematologyMayo ClinicRochesterNY
  2. 2.HematologyMayo ClinicRochesterNY

Personalised recommendations